MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-10-2022
Oyster Point Pharma P/E Ratio 2011-2026 | OYST
Annual P/E Ratio Oyster Point Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.85 | -1.22 | -3.2 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.22 | -3.2 | -2.42 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-2.15 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-0.183 | - | 1.35 % | $ 17.8 M |  China |
 |
Coherus BioSciences
CHRS
|
1.35 | $ 1.64 | 1.86 % | $ 192 M |  USA |
 |
AgeX Therapeutics
AGE
|
5.53 | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
-0.236 | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
2.49 K | - | 2.54 % | $ 160 B | France |
 |
BioNTech SE
BNTX
|
-19.4 | $ 92.25 | 0.12 % | $ 22.3 B | Germany |
 |
AstraZeneca PLC
AZN
|
16.3 | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-0.0167 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-18.5 | - | 0.74 % | $ 768 M |  Israel |
 |
Compugen Ltd.
CGEN
|
5.55 | $ 2.65 | -5.36 % | $ 248 M | Israel |
 |
Abcam plc
ABCM
|
-581 | - | - | $ 4.9 B | Britain |
|
Galera Therapeutics
GRTX
|
-0.403 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-251 | - | -18.52 % | $ 27.3 M | Britain |
|
Enlivex Therapeutics Ltd.
ENLV
|
0.0355 | $ 0.68 | -4.67 % | $ 31.1 M | Israel |
 |
Esperion Therapeutics
ESPR
|
-24.7 | $ 3.12 | -0.32 % | $ 649 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-121 | $ 31.29 | -3.99 % | $ 842 M | USA |
 |
Affimed N.V.
AFMD
|
-9.16 | - | -34.95 % | $ 21.5 M | Germany |
|
Forte Biosciences
FBRX
|
-4.83 | $ 21.94 | 1.62 % | $ 284 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-0.859 | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-0.259 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-1.19 | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
-1.41 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-0.18 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-2.12 | - | 0.23 % | $ 488 M | USA |
 |
Grifols, S.A.
GRFS
|
21.2 | $ 8.01 | - | $ 5.44 B |  Spain |
 |
Ayala Pharmaceuticals
AYLA
|
-0.203 | - | - | $ 7.46 M | Israel |
 |
Heron Therapeutics
HRTX
|
-9.92 | $ 0.88 | 2.85 % | $ 147 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
0.00975 | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-2.93 | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
-4.4 | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
-19.7 | $ 14.89 | 0.07 % | $ 214 M | USA |
 |
Advaxis
ADXS
|
-0.0388 | - | -9.65 % | $ 45.9 M | USA |
 |
InflaRx N.V.
IFRX
|
-1.39 | $ 2.74 | 4.98 % | $ 184 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-0.964 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-3.48 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.735 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-1.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.489 | $ 3.44 | 1.18 % | $ 5.66 M | Israel |
 |
Aptose Biosciences
APTO
|
-0.0913 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-0.146 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-16.1 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-0.189 | - | 4.14 % | $ 49.1 M | USA |